Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of Schizophrenia. Paliperidone palmitate, an investigational, once-monthly atypical antipsychotic injection, utilises Elan Drug Technologies NanoCrystal® technology.

The NanoCrystal® technology, a technology enabling the formulation of poorly water soluble compounds for all routes of administration, facilitated the development of a stable, low viscosity, high drug loaded formulation of paliperidone palmitate. The application of the NanoCrystal® technology has allowed for a ready-to-use one month duration intramuscular injectable formulation to be developed. This product was approved by the US Food and Drug Administration (FDA) earlier this year.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
New ingestible sensor for non-intrusive sleep disorder monitoring developed by MIT and collaborators